産婦人科領域におけるPipemidic acidの基礎的, 臨床的検討

抄録

Fundamental and clinical studies of pipemidic acid (PPA) were made with the following results.
1. In vitro antibacterial activity of PPA was compared with that of piromidic acid (PA), β-hydroxypiromidic acid (β-OHPA) and nalidixic acid (NA) using 242 strains isolated from various infections in the field of obstetrics and gynecology. Most of gram-negative bacteria were inhibited by 6.25 μg of PPA per ml which were generally more active than PA, β-OHPA and NA. About 50 % of pseudomonads was inhibited by 50 μg of PPA per ml, whereas more than 90% was resistant to 100 pg of PA, β-OHPA or NA per ml.
2. Concentrations of PPA in various tissues and body fluids were determined after a single oral administration of 250 mg. Its peak levels were about 2-3 μg/ml in maternal serum 2-4 hours after administration, about 2-μg/ml in amniotic fluid 3 hours, and about 2.7 μg/ml in maternal milk 2 hours. PPA was not detected in fetal tissues.
3. PPA was administered to 11 cases of infections at daily doses of 750-1, 000 mg for 5-45 days with favorable results in 7 cases (efficacy rate : 63.6%).
4. Side effects were not observed at all.